Alto Neuroscience (NYSE:ANRO) Shares Gap Down - Here's Why

Key Points

• Alto Neuroscience shares declined at the open, falling from a prior close of $36.30 to $35.00 before trading near $35.37.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating from 11 analysts and an average price target of $37.25, despite some sell ratings and target-price reductions.
• The company reported a quarterly loss of $0.65 per share, beating expectations for a $0.73 loss, while several institutional investors—including Perceptive Advisors and Orbimed Advisors—recently increased their holdings.

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) shares gapped down before the market opened on Friday . The stock had previously closed at $36.30, but opened at $35.00. Alto Neuroscience shares last traded at $35.37, with a volume of 22,504 shares changing hands.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on ANRO shares. Zacks Research raised Alto Neuroscience from a "strong sell" rating to a "hold" rating in a report on Thursday, August 20th. Bank of America initiated coverage on Alto Neuroscience in a report on Tuesday, May 5th. They set a "buy" rating and a $35.00 target price for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Alto Neuroscience in a research report on Wednesday, July 29th. Wall Street Zen upgraded shares of Alto Neuroscience from a "strong sell" rating to a "sell" rating in a report on Saturday, August 15th. Finally, Robert W. Baird reduced their price target on shares of Alto Neuroscience from $38.00 to $36.00 and set an "outperform" rating for the company in a research report on Monday, May 18th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $37.25.

Alto Neuroscience Stock Performance

The firm's 50 day moving average is $28.53 and its 200-day moving average is $24.04. The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of -14.69 and a beta of 1.06. The company has a debt-to-equity ratio of 0.07, a quick ratio of 14.85 and a current ratio of 14.85.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.08. Analysts forecast that Alto Neuroscience, Inc. will post -2.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alto Neuroscience

A number of large investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. grew its holdings in Alto Neuroscience by 14,567.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company's stock valued at $3,786,000 after purchasing an additional 211,222 shares during the period. Jennison Associates LLC acquired a new position in shares of Alto Neuroscience during the 1st quarter worth approximately $8,687,000. AWM Investment Company Inc. purchased a new position in shares of Alto Neuroscience during the 2nd quarter valued at approximately $2,111,000. Perceptive Advisors LLC lifted its position in shares of Alto Neuroscience by 12.6% during the 1st quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company's stock valued at $45,182,000 after buying an additional 225,500 shares in the last quarter. Finally, Orbimed Advisors LLC lifted its position in shares of Alto Neuroscience by 34.0% during the 1st quarter. Orbimed Advisors LLC now owns 167,500 shares of the company's stock valued at $3,765,000 after buying an additional 42,500 shares in the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source